GRACE: A conversational AI platform for geriatric oncology risk and capability evaluation.

A Arash Naeim (Division of Hematology-Oncology, Department of Medicine, University of California, Los Angeles) J Justin Cheng (University of Michigan Department of Hematology and Oncology, Wyoming, MI) B Brennan Spiegel (Cedars-Sinai Center for Virtual Medicine and Health System Transformation, Los Angeles, CA) A Alexandra Bakshian (UCLA Center for AI & SMART Health, CTSI, Los Angeles, CA) E Ella Tetrault (Cedars-Sinai Center for Virtual Medicine and Health System Transformation, Los Angeles, CA) M Muskaan Mehra (Cedars-Sinai Center for Virtual Medicine and Health System Transformation, Los Angeles, CA) D Dian Amini (UCLA Center for AI & SMART Health, CTSI, Los Angeles, CA) Z Zoe Krut (Cedars-Sinai Center for Virtual Medicine and Health System Transformation, Los Angeles, CA) H Helen Shang (UCLA Division of Hematology-Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA) M Mina S. Sedrak (UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, CA) A Alex Bui (UCLA Center for AI & SMART Health, CTSI, Los Angeles, CA) T Taylor Johnson (UCLA Embedded Clinical Research and Innovation Unit, CTSI, Los Angeles, CA) R Raymond Wang (Department of Pediatrics, University of California Irvine School of Medicine, Irvine) O Omer Liran (Cedars-Sinai Center for Virtual Medicine and Health System Transformation, Los Angeles, CA)

Abstract

1658 Background: Comprehensive geriatric assessment (CGA) is a multidimensional evaluation of health in older adults and endorsed by the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) for improved outcomes in geriatric cancer patients. However, CGA is underutilized due to time constraints and staffing shortages. Artificial intelligence (AI) can provide autonomous geriatric assessments (GA) but require validation. Methods: GRACE, an AI platform for GA via natural language interaction, was tested against manual GA. 70 adults aged ≥65 were enrolled from UCLA using the portal MyChart and at affiliated active senior living centers. 15 clinicians contributed qualitative perspectives. Concordance was evaluated using sensitivity, specificity, predictive values, and agreement (Cohen’s κ, Gwet’s AC1). Usability was measured with the System Usability Scale (SUS), and patient and provider interviews were thematically analyzed. Results: GRACE showed high diagnostic performance (sensitivity 0.73, specificity 0.94, κ=0.63, AC1=0.82) with highest agreement in polypharmacy (κ≈0.97; AC1≈0.98). Usability was high (SUS >80th percentile) and 84% of participants reported confidence using GRACE. Clinicians endorsed GRACE as a practical pre-visit intake tool that integrates with electronic health records and facilitates timely referrals. Conclusions: GRACE demonstrates that conversational AI can replicate key elements of clinician-administered GA while reducing burden on oncology teams. Larger multi-site studies are warranted to evaluate clinical impact and integration into routine oncology practice. Performance of GRACE versus manual geriatric assessment. Domain Sensitivity (CI) Specificity (CI) PPV (CI) NPV (CI) Cohen's Kappa (CI) Gwet's AC1 (CI) General Health 0.872 (0.748, 0.940) 0.931 (0.891, 0.957) 0.719 (0.592, 0.819) 0.973 (0.943, 0.988) 0.741 (0.637, 0.845) 0.887 (0.839, 0.935) Physical 0.859 (0.760, 0.922) 0.971 (0.956, 0.981) 0.753 (0.649, 0.834) 0.985 (0.973, 0.992) 0.781 (0.704, 0.858) 0.953 (0.935, 0.970) Functional 0.563 (0.332, 0.769) 0.985 (0.971, 0.993) 0.529 (0.310, 0.738) 0.987 (0.974, 0.994) 0.532 (0.298, 0.765) 0.972 (0.957, 0.986) Social Support 0.629 (0.530, 0.718) 0.873 (0.839, 0.900) 0.508 (0.420, 0.596) 0.918 (0.889, 0.940) 0.458 (0.359, 0.558) 0.753 (0.702, 0.805) Psychological 0.570 (0.460, 0.673) 0.920 (0.894, 0.940) 0.506 (0.404, 0.607) 0.937 (0.913, 0.955) 0.465 (0.353, 0.576) 0.839 (0.802, 0.876) Comorbidity 0.641 (0.484, 0.773) 0.996 (0.989, 0.998) 0.862 (0.694, 0.945) 0.985 (0.975, 0.991) 0.726 (0.601, 0.851) 0.980 (0.971, 0.989) Polypharmacy 0.974 (0.865, 0.995) 1.000 (0.893, 1.000) 1.000 (0.906, 1.000) 0.970 (0.847, 0.995) 0.971 (0.915, 1.027) 0.972 (0.916, 1.027) Overall 0.721 (0.674, 0.763) 0.956 (0.949, 0.963) 0.649 (0.603, 0.692) 0.968 (0.962, 0.974) 0.645 (0.604, 0.687) 0.917 (0.907, 0.927)

Article Details

Volume / Issue Vol. 44, Issue 16_suppl
Published June 01, 2026
Pages 1658-1658
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (14)

A

Arash Naeim

Division of Hematology-Oncology, Department of Medicine, University of California, Los Angeles

J

Justin Cheng

University of Michigan Department of Hematology and Oncology, Wyoming, MI

B

Brennan Spiegel

Cedars-Sinai Center for Virtual Medicine and Health System Transformation, Los Angeles, CA

A

Alexandra Bakshian

UCLA Center for AI & SMART Health, CTSI, Los Angeles, CA

E

Ella Tetrault

Cedars-Sinai Center for Virtual Medicine and Health System Transformation, Los Angeles, CA

M

Muskaan Mehra

Cedars-Sinai Center for Virtual Medicine and Health System Transformation, Los Angeles, CA

D

Dian Amini

UCLA Center for AI & SMART Health, CTSI, Los Angeles, CA

Z

Zoe Krut

Cedars-Sinai Center for Virtual Medicine and Health System Transformation, Los Angeles, CA

H

Helen Shang

UCLA Division of Hematology-Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA

M

Mina S. Sedrak

UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, CA

A

Alex Bui

UCLA Center for AI & SMART Health, CTSI, Los Angeles, CA

T

Taylor Johnson

UCLA Embedded Clinical Research and Innovation Unit, CTSI, Los Angeles, CA

R

Raymond Wang

Department of Pediatrics, University of California Irvine School of Medicine, Irvine

O

Omer Liran

Cedars-Sinai Center for Virtual Medicine and Health System Transformation, Los Angeles, CA